Last reviewed · How we verify
Moderate to Severe Plaque Psoriasis
Approved treatments
- Induction- PF-06480605 450 mg SC Q4W · Pfizer
PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions. - tumor necrosis factor inhibitors (TNFi) · Pfizer
- TNF Inhibitor · Pfizer
- Chronic- PF-06480605 50 mg SC Q4W · Pfizer
- Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Chronic- PF-06480605 150 mg SC Q4W · Pfizer
- Chronic- PF-06480605 150 mg SC Q4W · Pfizer
- Chronic- PF-06480605 450 mg SC Q4W · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to Severe Plaque Psoriasis patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to Severe Plaque Psoriasis treatment landscape brief
- Moderate to Severe Plaque Psoriasis treatment updates RSS
Frequently asked questions about Moderate to Severe Plaque Psoriasis
What drugs treat Moderate to Severe Plaque Psoriasis?
Tracked treatments include Induction- PF-06480605 450 mg SC Q4W, tumor necrosis factor inhibitors (TNFi), TNF Inhibitor, Chronic- PF-06480605 50 mg SC Q4W, Induction- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 450 mg SC Q4W.
What is the treatment for Moderate to Severe Plaque Psoriasis?
Standard treatment for Moderate to Severe Plaque Psoriasis includes Induction- PF-06480605 450 mg SC Q4W, tumor necrosis factor inhibitors (TNFi), TNF Inhibitor, Chronic- PF-06480605 50 mg SC Q4W, Induction- PF-06480605 150 mg SC Q4W. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderate to Severe Plaque Psoriasis patent cliff · Moderate to Severe Plaque Psoriasis CI report
- Treatment: Induction- PF-06480605 450 mg SC Q4W · Pfizer
- Treatment: tumor necrosis factor inhibitors (TNFi) · Pfizer
- Treatment: TNF Inhibitor · Pfizer
- Treatment: Chronic- PF-06480605 50 mg SC Q4W · Pfizer
- Treatment: Induction- PF-06480605 150 mg SC Q4W · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing